Capital Investment Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Capital Investment Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$576K	Hold	38,865	–	–	0.01%	456
2025 Q4	$620K	Hold	38,865	–	–	0.01%	431
2025 Q3	$429K	Hold	38,865	–	–	0.01%	505
2025 Q2	$329K	Sell	38,865 -1,000	-3%	-$8.02K	0.01%	539
2025 Q1	$321K	Hold	39,865	–	–	0.01%	531
2024 Q4	$358K	Hold	39,865	–	–	0.01%	481
2024 Q3	$292K	Hold	39,865	–	–	0.01%	520
2024 Q2	$228K	Hold	39,865	–	–	0.01%	558
2024 Q1	$200K	Sell	39,865 -725	-2%	-$4.92K	﹤0.01%	585
2023 Q4	$365K	Hold	40,590	–	–	0.01%	439
2023 Q3	$315K	Hold	40,590	–	–	0.01%	437
2023 Q2	$393K	Buy	40,590 +225	+0.6%	+$2.33K	0.01%	378
2023 Q1	$442K	Hold	40,365	–	–	0.01%	368
2022 Q4	$174K	Buy	40,365 +10,000	+33%	+$58K	0.01%	546
2022 Q3	$228K	Buy	30,365 +800	+3%	+$6.92K	0.01%	476
2022 Q2	$297K	Buy	29,565 +725	+3%	+$8.11K	0.01%	429
2022 Q1	$357K	Buy	28,840 +13,840	+92%	+$214K	0.01%	419
2021 Q4	$343K	Buy	15,000 +2,000	+15%	+$47.4K	0.01%	429
2021 Q3	$288K	Buy	13,000 +3,000	+30%	+$47.6K	0.01%	462
2021 Q2	$130K	Buy	+10,000	New	+$127K	﹤0.01%	554

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Capital Investment Advisors's AUPH Position: Q1 2026 in Review

Capital Investment Advisors held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2026 at 38,865 shares worth $576K. The position accounts for 0.01% of the portfolio, ranked #456.

Capital Investment Advisors first reported a position in AUPH in Q2 2021 and has held it in 20 quarters since. The position peaked at $620K in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

Capital Investment Advisors held 38,865 shares of Aurinia Pharmaceuticals worth $576K as of Q1 2026.
Capital Investment Advisors left its Aurinia Pharmaceuticals share count unchanged in Q1 2026.
Aurinia Pharmaceuticals made up 0.01% of Capital Investment Advisors's portfolio in Q1 2026, its #456 holding.
Capital Investment Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
Capital Investment Advisors's Aurinia Pharmaceuticals position peaked at $620K in Q4 2025.
259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Capital Investment Advisors's 13F filing for Q1 2026, filed 16 Apr 2026.